|
1
|
Huang MN, Yu H and Moudgil KD: The
involvement of heat-shock proteins in the pathogenesis of
autoimmune arthritis: a critical appraisal. Semin Arthritis Rheum.
40:164–175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
North RJ and Bursuker I: Generation and
decay of the immune response to a progressive fibrosarcoma. I.
Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+
effector T cells. J Exp Med. 159:1295–1311. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zang X and Allison JP: The B7 family and
cancer therapy: costimulation and coinhibition. Clin Cancer Res.
13:5271–5279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Greenwald RJ, Freeman GJ and Sharpe AH:
The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen YW, Tekle C and Fodstad O: The
immunoregulatory protein human B7H3 is a tumor-associated antigen
that regulates tumor cell migration and invasion. Curr Cancer Drug
Targets. 8:404–413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chavin G, Sheinin Y, Crispen PL, et al:
Expression of immunosuppresive B7-H3 ligand by hormone-treated
prostate cancer tumors and metastases. Clin Cancer Res.
15:2174–2180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Crispen PL, Sheinin Y, Roth TJ, et al:
Tumor cell and tumor vasculature expression of B7-H3 predict
survival in clear cell renal cell carcinoma. Clin Cancer Res.
14:5150–5157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roth TJ, Sheinin Y, Lohse CM, et al: B7-H3
ligand expression by prostate cancer: a novel marker of prognosis
and potential target for therapy. Cancer Res. 67:7893–7900. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamato I, Sho M, Nomi T, et al: Clinical
importance of B7-H3 expression in human pancreatic cancer. Br J
Cancer. 101:1709–1716. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun J, Chen LJ, Zhang GB, et al: Clinical
significance and regulation of the costimulatory molecule B7-H3 in
human colorectal carcinoma. Cancer Immunol Immunother.
59:1163–1171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zang X, Sullivan PS, Soslow RA, Waitz R,
Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, et al:
Tumor associated endothelial expression of B7-H3 predicts survival
in ovarian carcinomas. Mod Pathol. 23:1104–1112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang G, Xu Y, Lu X, Huang H, Zhou Y, Lu B
and Zhang X: Diagnosis value of serum B7-H3 expression in non-small
cell lung cancer. Lung Cancer. 66:245–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hashiguchi M, Kobori H, Ritprajak P, et
al: Triggering receptor expressed on myeloid cell-like transcript 2
(TLT-2) is a counter-receptor for B7-H3 and enhances T cell
responses. Proc Natl Acad Sci USA. 105:10495–10500. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Elango KJ, Anandkrishnan N, Suresh A, Iyer
SK, Ramaiyer SK and Kuriakose MA: Mouth self-examination to improve
oral cancer awareness and early detection in a high-risk
population. Oral Oncol. 47:620–624. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Silverman S Jr: Demographics and
occurrence of oral and pharyngeal cancers. The outcomes, the
trends, the challenge. J Am Dent Assoc. 132 (Suppl):7S–11S. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Regezi JA, Sciubba JJ and Jordan RCK: Oral
Pathology: Clinical Pathologic Correlations. 5th. Elsevier
Saunders; St. Louis, MO: 2007
|
|
17
|
Greenlee RT, Murray T, Bolden S and Wingo
PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carvalho AL, Magrin J and Kowalski LP:
Sites of recurrence in oral and oropharyngeal cancers according to
the treatment approach. Oral Dis. 9:112–118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Modjtahedi H: Molecular therapy of head
and neck cancer. Cancer Metastasis Rev. 24:129–146. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
De Roy PG: Helsinki and the Declaration of
Helsinki. World Med J. 50:9–11. 2004.
|
|
21
|
O'Sullivan B and Shah J: New TNM staging
criteria for head and neck tumors. Semin Surg Oncol. 21:30–42.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shuyi Y, Feng W, Jing T, et al: Human
beta-defensin-3 (hBD-3) upregulated by LPS via epidermal growth
factor receptor (EGFR) signaling pathways to enhance lymphatic
invasion of oral squamous cell carcinoma. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 112:616–625. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohigashi Y, Sho M, Yamada Y, et al:
Clinical significance of programmed death-1 ligand-1 and programmed
death-1 ligand-2 expression in human esophageal cancer. Clin Cancer
Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun J, Xu K, Wu C, et al: PD-L1 expression
analysis in gastric carcinoma tissue and blocking of
tumor-associated PD-L1 signaling by two functional monoclonal
antibodies. Tissue Antigens. 69:19–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Konishi J, Yamazaki K, Azuma M, et al:
B7-H1 expression on non-small cell lung cancer cells and its
relationship with tumor-infiltrating lymphocytes and their PD-1
expression. Clin Cancer Res. 10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hamanishi J, Mandai M, Iwasaki M, et al:
Programmed cell death 1 ligand 1 and tumor-infiltrating
CD8+ T lymphocytes are prognostic factors of human
ovarian cancer. Proc Natl Acad Sci USA. 104:3360–3365. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ghebeh H, Mohammed S, Al-Omair A, et al:
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in
breast cancer patients with infiltrating ductal carcinoma:
correlation with important high-risk prognostic factors. Neoplasia.
8:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krambeck AE, Thompson RH, Dong H, et al:
B7-H4 expression in renal cell carcinoma and tumor vasculature:
associations with cancer progression and survival. Proc Natl Acad
Sci USA. 103:10391–10396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tringler B, Zhuo S, Pilkington G, et al:
B7-h4 is highly expressed in ductal and lobular breast cancer. Clin
Cancer Res. 11:1842–1848. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nomi T, Sho M, Akahori T, et al: Clinical
significance and therapeutic potential of the programmed death-1
ligand/programmed death-1 pathway in human pancreatic cancer. Clin
Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zou W and Chen L: Inhibitory B7-family
molecules in the tumour microenvironment. Nat Rev Immunol.
8:467–477. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chapoval AI, Ni J, Lau JS, et al: B7-H3: a
costimulatory molecule for T cell activation and IFN-gamma
production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Prasad DV, Nguyen T, Li Z, Yang Y, Duong
J, Wang Y and Dong C: Murine B7-H3 is a negative regulator of T
cells. J Immunol. 173:2500–2506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsushima F, Tanaka K, Otsuki N, Youngnak
P, Iwai H, Omura K and Azuma M: Predominant expression of B7-H1 and
its immunoregulatory roles in oral squamous cell carcinoma. Oral
Oncol. 42:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leitner J, Klauser C, Pickl WF, et al:
B7-H3 is a potent inhibitor of human T-cell activation: No evidence
for B7-H3 and TREML2 interaction. Eur J Immunol. 39:1754–1764.
2009. View Article : Google Scholar : PubMed/NCBI
|
